Home » Stocks » Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. (ANTH)

Stock Price: $0.0370 USD -0.0060 (-13.95%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 968,623
Revenue (ttm) n/a
Net Income (ttm) -23.39M
Shares Out 26.18M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.0370
Previous Close $0.0430
Change ($) -0.0060
Change (%) -13.95%
Day's Open 0.0350
Day's Range 0.0340 - 0.0370
Day's Volume 55,063
52-Week Range 0.0161 - 0.0750

More Stats

Market Cap 968,623
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 26.18M
Float 26.13M
EPS (basic) -1.71
EPS (diluted) -1.76
FCF / Share -1.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.02M
Short Ratio 2.09
Short % of Float 10.45%
Beta 2.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.11
Revenue n/a
Operating Income -36.80M
Net Income -23.39M
Free Cash Flow -31.59M
Net Cash 8.09M
Net Cash / Share 0.31
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -141.96%
ROE -568.85%
ROIC 1,210.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.00*
Low
3.00
Current: $0.0370
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2017201620152014201320122011201020092008
Revenue-0.153.19-------
Revenue Growth--95.45%--------
Gross Profit-0.153.19-------
Operating Income-36.43-57.18-35.24-28.46-28.25-55.93-93.14-35.76-11.84-13.86
Net Income-26.87-55.52-35.22-29.60-30.86-45.33-99.07-40.41-12.20-18.10
Shares Outstanding10.285.164.452.722.280.900.580.360.020.02
Earnings Per Share-2.86-12.87-7.91-10.88-13.52-50.16-169.44-112.64-515.84-862.08
Operating Cash Flow-36.90-48.92-30.91-25.60-31.91-73.64-73.07-27.78-17.17-17.12
Capital Expenditures--0.77-0.08--0.02-0.21-1.35-0.02--0.01
Free Cash Flow-36.90-49.69-30.99-25.60-31.93-73.84-74.41-27.80-17.18-17.13
Cash & Equivalents2.2020.8446.952.6435.9524.7567.3763.383.807.94
Total Debt----17.8820.5524.33-13.13-
Net Cash / Debt2.2020.8446.952.6418.074.2043.0463.38-9.337.94
Assets3.6723.4748.133.4937.4226.4569.4965.265.898.03
Liabilities9.1710.628.475.7522.6629.9750.418.0118.178.49
Book Value-5.5012.4739.66-2.2614.76-3.5319.0857.26-12.28-0.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anthera Pharmaceuticals, Inc.
Country United States
Employees 21

Stock Information

Ticker Symbol ANTH
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ANTH
IPO Date March 1, 2010

Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.